BioGenex Will Introduce Fully Integrated miRNA-ISH System for Tumor Diagnosis and Clinical Research at the USCAP Annual Meeting in Seattle, WA
The system includes over 200 ready to use miRNA probes, detection kits, optimized protocols for visualization in FFPE and automation platforms.
FREMONT, Calif., March 7, 2016 /PRNewswire/ -- The discovery of microRNAs [miRNAs] has been one of the defining developments in cancer biology over the past decade. miRNAs are short, single stranded 20-22 nucleotide long, non-coding RNAs that regulate gene expression and have fundamental roles in Cancer growth and metastasis. miRNAs exert their function via base pairing with complementary mRNA molecules, resulting in gene silencing via transcriptional repression or target degradation. BioGenex solved the inherent difficulties in visualizing miRNAs in spatial context by using a propriety technology to synthesize modified, high-affinity oligonucleotides, labelling miRNA probes with multiple reporter molecules and developing a fully-integrated miRNA-ISH workflow solution allowing high throughput analysis of miRNA in the spatial context.
BioGenex's unique miRNA probes enable detection of single nucleotide mismatch thus allowing high sensitivity and specificity. Over 200 ready to use miRNA probes are now available, and more are being developed. BioGenex miRNA-ISH detection kits are optimized for miRNA detection with robust amplification of the signal producing clean intense staining. Each kit includes easy-to-follow protocols and ready-to-use reagents. Thanks to the high sensitivity and specificity of the probes, these kits can be used for either manual staining or high-throughput, automated staining and allow complete staining in 5-6 hours. In addition, BioGenex offers a negative control scramble probe, positive control U6 probe and positive control validated tissue slides for each miRNA. Unlike PCR based techniques, BioGenex in situ hybridization system has the ability to generate robust chromogenic signal while preserving the spatial context of the tissue sample. This provides a powerful tool for precise tumor characterization and a breakthrough for clinical research and analysis of cancer of unknown primary (CUP), poorly differentiated or undifferentiated tumors, and cancer staging. In recent years, BioGenex initiated multiple collaborative projects and released several publications providing robust evidence to the usefulness of this technology and its potential as the future for cancer diagnostics and precision medicine (read more)
BioGenex will introduce the integrated miRNA system, together with the Xmatrx automation platforms, at the USCAP annual meeting in Seattle (WA) next week. "miRNA in situ visualization offers the opportunity to potentially reduce cancer death by 10% over the next decade by accurate tumor characterization," said Krishan Kalra, Founder and CEO of BioGenex.
BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biogenex-will-introduce-fully-integrated-mirna-ish-system-for-tumor-diagnosis-and-clinical-research-at-the-uscap-annual-meeting-in-seattle-wa-300231351.html
SOURCE BioGenex Laboratories Inc.